FEMARA
Femara is not a company but a brand-name prescription drug, letrozole, used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is an aromatase inhibitor that works by reducing estrogen production in the body. Femara was first approved by the U.S. Food and Drug Administration in 1997 for advanced breast cancer and later for adjuvant therapy. The drug is manufactured and marketed by the Swiss pharmaceutical giant Novartis AG. Despite its prominence in oncology, no independent business entity named Femara exists in any sector, including iGaming or gambling. The confusion likely arises from the drug's brand name being mistaken for a company name. All public references to Femara exclusively pertain to the medication, its clinical trials, and its regulatory history.
Detailed Review
Femara is a prescription pharmaceutical product, not a company, and therefore lacks a corporate history, leadership team, headquarters, or employee headcount. The active substance, letrozole, was developed by the pharmaceutical company Ciba-Geigy (now part of Novartis) and received its first FDA approval in 1997 for the treatment of advanced breast cancer. Over subsequent years, indications expanded to include adjuvant therapy for early-stage hormone receptor-positive breast cancer and extended adjuvant therapy. Femara is one of several aromatase inhibitors on the market, competing with anastrozole (Arimidex) and exemestane (Aromasin). The drug has been available as a generic since 2011, when Mylan launched the first generic version. Novartis AG, headquartered in Basel, Switzerland, holds the marketing authorization for Femara in numerous countries. The European Medicines Agency has also reviewed and approved Femara for use in the EU. Because Femara is a drug brand and not a company, there are no products, platforms, or brands operated under that name, and no executive officers or employees are associated with it as a corporate entity. All searches for a company named Femara in business registers, industry news, and company databases returned no results, confirming the misinterpretation.
Key Products
Femara® (letrozole) 2.5 mg tablets
Aromatase inhibitor for hormone‑receptor‑positive breast cancer in postmenopausal women. Also used off‑label for ovulation induction.
Letrozole (generic)
Generic version available under various labels; also used off‑label for fertility.